FDA Classifies AI System for Cervical Cytology Imaging

The FDA has classified an AI-powered digital cervical cytology slide imaging system into Class II, effective November 5, 2026. This regulatory action aims to ensure the device's safety and effectiveness while reducing regulatory burdens by placing it in a lower classification than the automatic Class III. The move is intended to enhance patient access to innovative diagnostic tools.